Cellectis (CLLS) Net Income Growth (1y) (2016 - 2026)
Cellectis (CLLS) Net Income Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 63.48% |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 1,228.66% |
| 10 | Cellectis | 285.51 Mn | 99.84 Mn | - | 2.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.00% |
| Dec 31, 2025 | -155.80% |
| Sep 30, 2025 | 188.81% |
| Jun 30, 2023 | -78.13% |
| Mar 31, 2023 | 16.52% |
| Dec 31, 2022 | 57.03% |
| Sep 30, 2022 | 87.17% |
| Jun 30, 2022 | 265.42% |
| Mar 31, 2022 | 43.97% |
| Dec 31, 2021 | 87.11% |
| Sep 30, 2021 | -47.29% |
| Jun 30, 2021 | -3.08% |
| Mar 31, 2021 | -173.42% |
| Dec 31, 2020 | -42.15% |
| Sep 30, 2020 | -55.89% |
| Jun 30, 2020 | 4.49% |
| Mar 31, 2020 | 177.07% |
| Dec 31, 2019 | -28.89% |
| Sep 30, 2019 | 23.98% |
| Jun 30, 2019 | -287.53% |